Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 115 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Physical Therapy Evaluation Clear all

Conditions: Glioblastoma Multiforme, GBM
Interventions: 18F-FET; Drug
Lead sponsor: Marcelo F. Di Carli, MD, FACC; Other
Eligibility: 18 Years to 85 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obsessive Compulsive Disorder
Interventions: sertraline, psychotherapy; Drug · Behavioral
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 6 Years to 16 Years
Enrollment: 941 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 44
States / cities: Dothan, Alabama • Imperial, California • Los Angeles, California + 39 more

Conditions: Facial Papulopustular Rosacea
Interventions: FMX103 minocycline foam 1.5%, Vehicle foam; Drug
Lead sponsor: Vyne Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 751 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 54
States / cities: Tucson, Arizona • Fremont, California • Los Angeles, California + 46 more

Conditions: Scars
Interventions: Tixel C; Device
Lead sponsor: Novoxel Ltd.; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Fibromyalgia
Interventions: Treatment for Fibromyalgia; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 49
States / cities: Hot Springs, Arkansas • Santa Barbara, California • Danbury, Connecticut + 46 more

Conditions: Glioblastoma
Interventions: MRI with Arterial Spin Labeling (ASL); Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Holistic Care, Mental Health, Sleep, PTSD, Depression - Major Depressive Disorder, Anxiety, Resilience, Recovery, Occupation, Biometrics Measurement, Veteran, Quality of Life
Interventions: Not listed
Lead sponsor: Baylor University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Waco, Texas

Conditions: Achilles Tendinopathy
Interventions: Shockwave Therapy, Photobiomodulation Therapy, Physical Therapy; Device · Other
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Healthy Normals
Interventions: Rehabilitation Measurement Tool; Device
Lead sponsor: Reflexion Health, Inc.; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2012
U.S. locations: 1
States / cities: San Diego, California

Conditions: Prostate Cancer
Interventions: SPECT CT, 18F-DCFPyL PET/CT, 18F-NaF PET/CT, WB-MRI; Procedure · Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Baltimore, Maryland • Philadelphia, Pennsylvania

Conditions: Other Disorders of Glucose Regulation and Pancreatic Internal Secretion, Pancreatic Cancer
Interventions: Questionnaires, Nutritional Questionnaire and Nutritional Counseling, Booklet, Aerobic Exercise and Strength Training Exercises, Phone Calls, Physical Assessments; Behavioral · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Renal Cell Carcinoma
Interventions: MRI with ASL, ASL-MRI; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Anticoagulant Reversal, Reversal of Edoxaban Induced Anticoagulation
Interventions: PER977, Placebo; Drug
Lead sponsor: Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8
Interventions: Best Practice, Biospecimen Collection, Communication Intervention, Comprehensive Geriatric Assessment, Electronic Health Record Review, Survey Administration; Other · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 60 Years and older
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2031
U.S. locations: 3
States / cities: Duarte, California • Rochester, New York • Columbus, Ohio

Conditions: Duchenne Muscular Dystrophy
Interventions: delandistrogene moxeparvovec, placebo; Genetic
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: Male only
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 14
States / cities: Little Rock, Arkansas • Palo Alto, California • Sacramento, California + 11 more

Conditions: Low Back Pain
Interventions: Intracept Treatment, Sham Treatment; Device
Lead sponsor: Relievant Medsystems, Inc.; Industry
Eligibility: 25 Years to 70 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 13
States / cities: Phoenix, Arizona • Daly City, California • Long Beach, California + 10 more

Conditions: Opioid Induced Bowel Dysfunction
Interventions: Naldemedine, Placebo; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Binge Eating Disorder Associated With Obesity
Interventions: Zonegran, sugar pill; Drug
Lead sponsor: Lindner Center of HOPE; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Pain
Interventions: morphine sulfate extended release capsules; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 21 Years and older
Enrollment: 1,570 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 378
States / cities: Adamsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 314 more

Conditions: Acute Kidney Injury
Interventions: Not listed
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: Not listed
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Alopecia, Anxiety, Breast Carcinoma, Cognitive Side Effects of Cancer Therapy, Colorectal Carcinoma, Depression, Fatigue, Lung Carcinoma, Nausea and Vomiting, Pain, Psychological Impact of Cancer, Sleep Disorder, Weight Change
Interventions: Quality-of-Life Assessment, Yoga; Procedure
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2016
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Arthroplasty
Interventions: Tapentadol IR (CG5503), Placebo, Oxycodone HCL IR; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 45
States / cities: Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 42 more

Conditions: Cerebral Palsy
Interventions: START-Play Physical Therapy, Usual Care Physical Therapy; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 8 Months to 24 Months
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 4
States / cities: Los Angeles, California • Omaha, Nebraska • Richmond, Virginia + 1 more

Conditions: Parkinson's Disease, Motor Symptoms
Interventions: APOKYN, Physical Therapy; Drug · Behavioral
Lead sponsor: MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 12
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Loma Linda, California + 9 more

Search by objective public record fields.

FET-PET for Evaluation of Response of Recurrent GBM to Avastin

Sertraline Pediatric Registry for the Evaluation of Safety (SPRITES)

A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

Clinical Study to Evaluate the Safety and Effectiveness of the Treatment With Tixel C on Acne Scars

Fibromyalgia Health Outcome Study on Cost of Treatments

Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in Glioblastoma

Using Integrated Care and Wearable Technology to Evaluate Outcomes of the Shields & Stripes Program for Veterans and First Responders

Pilot Investigation to Evaluate Effectiveness of Shockwave Therapy, Photobiomodulation and Physical Therapy in the Management of Non-insertional Achilles Tendinopathy

Usability and Reliability of a New Physical Therapy Tool

Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to Therapy

PancFit: Multimodal Exercise During Preoperative Therapy for Pancreatic Cancer

Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in Metastatic Renal Cell Carcinoma

Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban

Evaluation of Geriatric Assessment and Management for Older Adults With Non-small Cell Lung Cancer Receiving Chemotherapy Radiation Therapy

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

SMART Clinical Study: Surgical Multi-center Assessment of RF Ablation for the Treatment of Vertebrogenic Back Pain

Study to Evaluate the Safety and Efficacy of Naldemedine (S-297995) for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain

Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity

Evaluation of Risk Minimization, Assessment and Outcomes in Patients With Chronic Pain Taking Avinza

Evaluation of Catheter Placement for Renal Replacement Therapy in Patients With Acute Kidney Injury

Yoga-Based Rehabilitation Program in Reducing Physical and Emotional Side Effects in Patients With Cancer

A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety

Efficacy of a Physical Therapy Intervention Targeting Sitting and Reaching for Young Children With Cerebral Palsy

Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN®